Openbookopenbook
Equity
ATEC
+0.0 · +0.00%
USD · NASDAQ

Alphatec Holdings Inc(ATEC) Stock Analysis | Healthcare

USD --+0.00%
Reward59Moderate
Risk58Medium-High
75%Data
Thin -14% profit margin · Revenue growing 15% YoY
Profitless Growth
Market Cap:1.46Bn
ⓘ
Reward Rating
59
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
58
Medium-High
Risk Assessment
5 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ATEC to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ATEC, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $15.79.

What is Alphatec Holdings Inc?

, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally.

ATEC · Verdict

Solid reward · elevated risk

ATEC's standout is growth; balance sheet and cash flow weigh on the picture.

Based on 88% data coverage

ATEC · Verdict

What’s working & what to watch

Strengths 1

  • Growth78/100

    Rev +29.6% CAGR · earnings -1.8%

Watchouts 3

  • Balance sheet27/100

    Current ratio 2.06

  • Cash flow40/100

    0% free-cash-flow margin

  • Profitability44/100

    -19% net margin · -373% ROE

Model-based scoring. For information only — not financial advice.

What is Alphatec Holdings Inc?

, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.46B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (59)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

FDMDFSmall Cap / 1.5B market cap
4DMedical Limited
Compare
ENOVSmall Cap / 1.5B market cap
Enovis Corp
Compare
CNMDSmall Cap / 1.5B market cap
CONMED Corporation
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap1.46B
P/E RatioN/A
Dividend YieldN/A
Beta0.855
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
5629,189 shares
$7.8M
0
6-9months
151,302,361 shares
$26.4M
0
9-12months
0
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.